ArticleAnnals of hematology2026
Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This retrospective, single‑center study evaluated the efficacy and safety of a reduced‑dose melphalan conditioning regimen (140–180 mg/m2) for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) ineligible for the standard dose (200 mg/m2). Clinical outcomes were compared between patients receiving reduced‑dose versus standard‑dose melphalan over a five-year period, with pre‑specified subgroup analyses based on age and renal function. The results demonstrated that despite less favorable baseline characteristics in the reduced-dose group, both overall survival (OS) and progression-free survival (PFS) met comparable criteria relative to the standard group. The reduced-dose regimen was associated with a significantly improved safety profile, characterized by lower rates of mucositis, fewer febrile episodes, and accelerated platelet engraftment. In conclusion, for MM patients unable to tolerate standard-dose conditioning, particularly those with compromised baseline status, a reduced-dose melphalan regimen offers a clinically effective and safer alternative that maintains therapeutic efficacy while reducing treatment-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.